MACCEMajor Adverse Cardiovascular and Cerebrovascular Event (cardiology)
MACCEMajor Adverse Cardiac and Cerebrovascular event
MACCEMissouri Advisory Council of Certification for Educators
MACCEMassachusetts Association of Chamber of Commerce Executives
MACCEMaine Association of Chamber of Commerce Executives
MACCEMember of Australian Council for Computers in Education
References in periodicals archive ?
MACCE were defined as a composite of all-cause death, myocardial infarction (MI), unplanned target vessel revascularization (TVR), ST, and stroke.
Conclusions: Our results suggest that in patients undergoing percutaneous coronary intervention with stent implantation, smoking is not associated with ISR and MACE; however, smoking is an independent risk factor for MACCE.
7] The Arterial Revascularization Therapy Study II trial has demonstrated that CABG therapy reduced the incidence of repeat revascularization and overall MACCE, but it did not influence the hard end points, such as death and MI, compared to treatment with SES.
The trial results were also analyzed based on the SYNTAX Score, which demonstrated no statistically significant difference in MACCE for patients in the lower two terciles - those with low lesion complexity (19.
The gender analysis, a secondary-endpoint evaluation in the real-world CoreValve ADVANCE Study, found that survival rates were nearly identical between genders, with no statistical differences in 30-day and 6-month all-cause mortality, cardiovascular mortality or the 30-day MACCE endpoint (Major Adverse Cardiac & Cerebrovascular Events, a composite of all-cause mortality, myocardial infarction, emergent cardiac surgery or percutaneous re-intervention, and stroke).
9 percent and MACCE (Major Adverse Cardiac & Cerebrovascular Events) rates of 8.
After 12 months, subjects who are free from all MACCE or major bleeding events will be randomized 1:1 to either placebo or ongoing dual antiplatelet therapy for an additional 18 months followed by three months of observational follow-up.
Our most recent analysis, presented today at SCAI, shows a significant reduction in MACCE in favor of Impella.
The study protocol was for low ejection fraction (EF) patients with unprotected left main (EF 35%) or with triple vessel disease (EF 30%), measuring a primary endpoint of 10 major adverse event (MAE) components including MACCE at 30 days for a total of 654 patients.